Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A second generation antihistamine, derived from piperazine and hydroxyzine metabolite, with minimal sedative effects and very low toxicity even at high doses.
No problems were detected in the short or long term in an infant whose mother took it during the first month after delivery as part of the treatment for pemphigus (Westermann 2012).
Its high binding to plasma proteins makes its transfer to milk very unlikely.
The British Society for Allergy and Clinical Immunology and other experts consider it safe during breastfeeding (Butler 2014, Powell 2007).